Prihlásiť sa Zaregistrujte sa zadarmo

Last updated: 17 May 2024 at 5:25pm EST

Joseph Limber Net Worth




The estimated Net Worth of Joseph M Limber is at least $2.22 Milión dollars as of 28 May 2016. Mr. Limber owns over 2,800 units of XOMA Royalty stock worth over $2,060,388 and over the last 12 years he sold XOMA stock worth over $0. In addition, he makes $159,992 as Independent Director at XOMA Royalty.

Mr. Limber XOMA stock SEC Form 4 insiders trading

Joseph has made over 6 trades of the XOMA Royalty stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 2,800 units of XOMA stock worth $75,936 on 28 May 2016.

The largest trade he's ever made was exercising 5,600 units of XOMA Royalty stock on 12 December 2015 worth over $151,872. On average, Joseph trades about 1,200 units every 39 days since 2012. As of 28 May 2016 he still owns at least 75,973 units of XOMA Royalty stock.

You can see the complete history of Mr. Limber stock trades at the bottom of the page.





Joseph Limber biography

Joseph M. Limber serves as Independent Director of the Company. Mr. Limber has been a director since December 2012. Mr. Limber currently serves as President and Chief Executive Officer and a member of the Board of Directors of Secura Bio, Inc., a position he has held since February 2019. Prior to that, Mr. Limber served as President and Chief Executive Officer of Genoptix, Inc. from March 2017 through December 2018. Mr. Limber served as Executive Chairman of ImaginAb from January 2016 through November 2017. Mr. Limber served as President and Chief Executive Officer of Gradalis, Inc. from July 2013 through April 2015. Mr. Limber served as President and Chief Executive Officer of Prometheus Laboratories Inc., a subsidiary of Nestlé Health Science, from December 2003 through April 2013 and as a member of its Board of Directors from January 2004 through April 2013. From January 2003 to July 2003, Mr. Limber was a consultant and interim Chief Executive Officer for Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry. From April 1998 to December 2002, Mr. Limber was the President and Chief Executive Officer of ACLARA BioSciences, Inc. (now Monogram Biosciences, Inc.), a developer of assay technologies and lab-on-a-chip systems for life science research. From 1996 to 1998, he was the President and Chief Operating Officer of Praecis Pharmaceuticals, Inc. (acquired by GlaxoSmithKline plc), a biotechnology company focused on the discovery and development of pharmaceutical products. Prior to Praecis, Mr. Limber served as Executive Vice President of SEQUUS Pharmaceuticals, Inc. (acquired by Alza Corporation and now part of the Johnson & Johnson family of companies). He also held management positions in marketing and sales with Syntex Corporation (now F. Hoffmann-La Roche Ltd.) and with Ciba-Geigy Corporation (now Novartis AG). Mr. Limber holds a B.A. from Duquesne University.

What is the salary of Joseph Limber?

As the Independent Director of XOMA Royalty, the total compensation of Joseph Limber at XOMA Royalty is $159,992. There are 7 executives at XOMA Royalty getting paid more, with James Neal having the highest compensation of $1,479,560.



How old is Joseph Limber?

Joseph Limber is 67, he's been the Independent Director of XOMA Royalty since 2012. There are 1 older and 7 younger executives at XOMA Royalty. The oldest executive at XOMA Royalty Corp. is W. Denman Van Ness, 77, who is the Independent Chairman of the Board.

What's Joseph Limber's mailing address?

Joseph's mailing address filed with the SEC is C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE, CA, 94608.

Insiders trading at XOMA Royalty

Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.



What does XOMA Royalty do?

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.



What does XOMA Royalty's logo look like?

XOMA Royalty Corp. logo

Complete history of Mr. Limber stock trades at XOMA Royalty

Dátum
#
Spoločnosť
 Človek
Trans.
Transakcia
 Počet akcií Cena za akciu Celková cena Počet akcií po Zdroj
28 May 2016 XOMA XOMA Royalty Corp. Joseph M Limber
Využitie opcie 2,800 $14.00 $39,200
28 May 2016
75,973 ↗
12 Dec 2015 XOMA XOMA Royalty Corp. Joseph M Limber
Využitie opcie 5,600 $25.40 $142,240
12 Dec 2015
73,173 ↗
28 May 2015 XOMA XOMA Royalty Corp. Joseph M Limber
Využitie opcie 2,800 $71.60 $200,480
28 May 2015
67,573 ↗
12 Dec 2014 XOMA XOMA Royalty Corp. Joseph M Limber
Využitie opcie 5,600 $93.60 $524,160
12 Dec 2014
27,900 ↗
28 May 2014 XOMA XOMA Royalty Corp. Joseph M Limber
Využitie opcie 2,800 $82.80 $231,840
28 May 2014
16,800 ↗
10 Mar 2014 XOMA XOMA Royalty Corp. Joseph M Limber
Využitie opcie 5,600 $128.60 $720,160
10 Mar 2014
5,600 ↗


XOMA Royalty executives and stock owners

XOMA Royalty executives and other stock owners filed with the SEC include: